Comparative Pharmacology
Head-to-head clinical analysis: EPLERENONE versus KAPSPARGO SPRINKLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPLERENONE versus KAPSPARGO SPRINKLE.
EPLERENONE vs KAPSPARGO SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective aldosterone receptor antagonist (mineralocorticoid receptor antagonist). Binds to the mineralocorticoid receptor, blocking the effects of aldosterone, leading to decreased sodium reabsorption and potassium excretion in the kidney.
Sodium-glucose cotransporter-2 (SGLT2) inhibitor; reduces glucose reabsorption in renal proximal tubules, increasing urinary glucose excretion and lowering blood glucose.
50 mg orally once daily, may increase to 50 mg twice daily after 4 weeks if tolerated; maximum 100 mg daily.
5 mg to 25 mg per day administered orally. For children below 80 kg, starting dose is 0.2 mg per kg per day. Maximum dose is 25 mg per day.
None Documented
None Documented
Clinical Note
moderateEplerenone + Digoxin
"The therapeutic efficacy of Digoxin can be decreased when used in combination with Eplerenone."
Clinical Note
moderateEplerenone + Digitoxin
"The therapeutic efficacy of Digitoxin can be decreased when used in combination with Eplerenone."
Clinical Note
moderateEplerenone + Deslanoside
"The therapeutic efficacy of Deslanoside can be decreased when used in combination with Eplerenone."
Clinical Note
moderateEplerenone + Acetyldigitoxin
Terminal elimination half-life is approximately 4 to 6 hours; in patients with heart failure or renal impairment, half-life may be prolonged (up to 8-12 hours). The short half-life supports twice-daily dosing.
Terminal elimination half-life is 11-13 hours in healthy adults, 17-19 hours in elderly patients; clinically relevant for once-daily dosing.
Approximately 67% of an oral dose is excreted in urine as metabolites (primarily inactive glucuronide conjugates) and approximately 32% in feces via biliary elimination; less than 5% of the dose is excreted unchanged in urine.
Primarily renal excretion as unchanged drug (40-50%) and metabolites; fecal elimination accounts for <5%.
Category C
Category C
Aldosterone Antagonist
Aldosterone Antagonist
"The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Eplerenone."